Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1455)	2/23/2000 9:29:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

Wednesday February 23, 6:30 am Eastern Time Company Press Release SOURCE: Incyte Pharmaceuticals, Inc. Incyte Announces $422 Million Private Placement PALO ALTO, Calif., Feb. 23 /PRNewswire/ -- Incyte Pharmaceuticals, Inc. (Nasdaq: INCY - news) announced today that it has entered into a definitive purchase agreement for the sale of two million shares of newly issued common stock to selected institutional investors for $422 million. The purchase price is $211.00 per share. Incyte stated that it expects to use the net proceeds of the offering for working capital and general corporate purposes. Proceeds may also be used to make strategic investments, acquire or license technology or products, or acquire businesses that may complement its business. (snip)

To: scaram(o)uche who wrote (1455)	2/23/2000 9:30:00 AM
From: scaram(o)uche	Respond to of 4974

Tuesday February 22, 4:56 pm Eastern Time Company Press Release SOURCE: Signal Pharmaceuticals, Inc. Signal Pharmaceuticals, Inc. Files Registration Statement For Initial Public Offering SAN DIEGO, Feb. 22 /PRNewswire/ -- Signal Pharmaceuticals, Inc. (''Signal'' or the ''Company''; proposed Nasdaq NMS: SGNL) announced today that it filed a registration statement with the Securities and Exchange Commission for an initial public offering of $70 million of shares of its common stock. All of the shares being offered are being sold by the Company. The offering will be managed by FleetBoston Robertson Stephens, Chase H&Q, a division of Chase Securities Inc., and CIBC World Markets Corp. Signal is a biopharmaceutical company focused on discovering, developing and commercializing new classes of small molecule drugs that regulate genes associated with disease. Signal's efforts are directed toward the areas of cancer, inflammatory disease, osteoporosis, cardiovascular disease, neurological disease and viral infections, all of which are disease areas in which abnormal gene regulation plays an important role in the onset and progression of disease. (snip)